← All Rezolute, INC filings

Rezolute, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RZLT
Rezolute, INC
10-K: Rezolute's Ersodetug Advances, Secures $107M Capital
Rezolute, Inc. reports significant progress in its ersodetug clinical trials for hyperinsulinism, securing over $107 million in net proceeds from recent equity financings, despite ongoing net losses.
NASDAQ
RZLT
Rezolute, INC
10-K: Rezolute, Inc. Files 10-K, Highlights Progress in Clinical Trials and Financial Position
Rezolute, Inc.'s annual 10-K filing details the company's clinical advancements, financial status, and future plans, including progress in Phase 3 trials for its lead drug candidate.